Asset Management One Co. Ltd. Has $9.36 Million Stock Holdings in Insulet Corporation $PODD

Asset Management One Co. Ltd. increased its position in Insulet Corporation (NASDAQ:PODD) by 7.0% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 29,779 shares of the medical instruments supplier’s stock after purchasing an additional 1,955 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Insulet were worth $9,356,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after buying an additional 178,976 shares during the period. American Century Companies Inc. boosted its stake in Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Groupama Asset Managment boosted its stake in Insulet by 0.4% during the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock valued at $276,728,000 after purchasing an additional 3,759 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Insulet by 4.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock valued at $177,096,000 after purchasing an additional 27,408 shares during the last quarter. Finally, Federated Hermes Inc. boosted its stake in Insulet by 23.4% during the 1st quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier’s stock valued at $166,198,000 after purchasing an additional 120,197 shares during the last quarter.

Insulet Trading Up 1.5%

NASDAQ:PODD opened at $325.80 on Tuesday. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $22.93 billion, a PE ratio of 99.03, a price-to-earnings-growth ratio of 2.68 and a beta of 1.40. The firm’s 50 day moving average is $327.65 and its 200 day moving average is $305.54. Insulet Corporation has a 12 month low of $227.03 and a 12 month high of $353.50.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet’s revenue was up 32.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PODD. Rothschild & Co Redburn lifted their price target on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Citigroup reiterated a “buy” rating on shares of Insulet in a research note on Tuesday, July 8th. The Goldman Sachs Group cut their price target on Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, October 1st. Finally, Leerink Partners lifted their price target on Insulet from $339.00 to $355.00 and gave the company an “outperform” rating in a research note on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $352.11.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.